Browse the evidence

GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant weight loss (8-21%) but discontinuation leads to rapid weight regain (approx. two-thirds) and return of cardiovascular risk factors, necessitating long-term maintenance strategies.

GLP-1 medications are highly effective for weight loss but are not a one-time fix. You must plan for long-term use or a structured maintenance program to prevent weight regain. Discuss with your doctor how to manage side effects (like nausea) through diet and titration, and ensure you have a plan for ongoing care, as stopping the medication often leads to regaining two-thirds of the lost weight.

GLP-1 receptor agonists (GLP1RAs) reduce the risk of total stroke by approximately 16-17% and non-fatal stroke by 15-16% in patients with type 2 diabetes, independent of their effects on weight loss.

If you have type 2 diabetes and are at high risk for heart disease or stroke, ask your doctor about GLP-1 receptor agonists. These medications not only help with blood sugar and weight but have been shown in large studies to significantly lower your risk of having a stroke. This benefit exists even if you don't lose a lot of weight.

GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.

GLP-1 medications like Semaglutide are powerful tools for weight loss and fixing metabolic issues, but they are not a one-time cure. If you stop taking them, you will likely regain most of the weight. Use them to stabilize your health and weight before considering skin removal surgery, or commit to long-term use if surgery is not an option.

Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.

If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.

GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.

GLP-1 and GIP/GLP-1 agonists offer significant cardiovascular and renal benefits, reducing the risk of heart attacks, strokes, and heart failure hospitalizations. These benefits occur independently of weight loss, suggesting direct protective effects on organs. They are recommended for patients with obesity and cardiovascular disease or heart failure.

Obesity and central adiposity drive insulin resistance and hypertension through the dysregulation of adipokines (elevated TNF-α, IL-6, leptin; reduced adiponectin), which activate inflammatory pathways like NF-κB and RAAS.

Excess body fat, especially around the abdomen, releases inflammatory hormones (adipokines) that block insulin action and raise blood pressure. This biological process, driven by cytokines like TNF-α and IL-6, makes weight loss and blood sugar control harder. Addressing obesity through lifestyle changes or medications that target these pathways can improve insulin sensitivity and reduce cardiovascular risk.

Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Resmetirom is a new daily pill option. It works by targeting liver-specific thyroid receptors to reduce inflammation and scarring, and it also lowers bad cholesterol. You do not need to lose a lot of weight for it to work on the liver, though diet and exercise are still recommended.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart failure hospitalizations in patients with type 2 diabetes and obesity, with specific benefits observed in heart failure with preserved ejection fraction (HFpEF).

If you have Type 2 Diabetes and Obesity, especially with heart issues, GLP-1 medications like Semaglutide or Liraglutide are highly effective. They not only help with weight loss but significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations. While injections can cause temporary stomach issues, the long-term protection for your heart is substantial. Discuss these options with your doctor, particularly if you have heart failure with preserved ejection fraction.

Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.

If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.

Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.

Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.

If you have type 2 diabetes and kidney disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications not only help with blood sugar and weight but also significantly slow the progression of kidney damage and reduce the risk of heart problems and death. While side effects like nausea and high costs can be barriers, the long-term benefits for kidney and heart health are substantial and supported by major clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.

If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.

Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.

If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.

GLP-1 receptor agonists (semaglutide, liraglutide) significantly improve cardiovascular biomarkers—including hs-CRP, systolic blood pressure, and lipid profiles—independent of glycemic control.

GLP-1 medications like semaglutide do more than just help you lose weight; they directly improve your heart health markers. They significantly lower systemic inflammation (hs-CRP), improve blood vessel function, lower blood pressure, and improve lipid profiles. These benefits happen even if you don't have diabetes, proving the drug protects your blood vessels directly. You should be aware of the slightly increased risk of gallbladder issues due to rapid weight loss, so your doctor will monitor your baseline risk.

GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).

GLP1-RAs may enhance mental health quality of life in this population.

The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.

Practitioners should consider the growing preference for semaglutide in obesity treatment.

Tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduces Obstructive Sleep Apnea severity (AHI) and improves cardiometabolic biomarkers in patients with moderate-to-severe OSA and obesity, leading to FDA approval for this indication.

If you have moderate-to-severe sleep apnea and obesity, ask your doctor about tirzepatide. It is an FDA-approved treatment that reduces breathing interruptions during sleep and improves heart health markers. It requires weekly injections and lifestyle counseling, but offers a viable alternative or adjunct to CPAP for those struggling with adherence or residual symptoms.

Patients treated with GLP-1 RAs experienced a lower occurrence of sight-threatening complications, including blindness (HR, 0.77; 95% CI, 0.73-0.82).

GLP-1 RAs may help reduce the risk of severe ocular complications in T2D patients.

GLP-1 RA use was associated with reduced headaches (RR, 0.45; 95% CI, 0.35-0.58; P < .001).

GLP-1 RAs may help alleviate headache symptoms in IIH patients.